Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Concert Pharmaceuticals

Thumbnail
September 03, 2019

Concert squares up to Pfizer in alopecia Jak bout

Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.

Thumbnail
July 31, 2019

Aclaris’s alopecia Jak might not be worth its Salt

Article image
Vantage logo
June 17, 2019

Incyte hopes its cream can rise to the top

Article image
Vantage logo
April 09, 2019

Concert out of tune after patent stumble

Article image
Vantage logo
February 26, 2019

Xeljanz warning Jaks up safety concerns

An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.

Article image
Vantage logo
November 12, 2018

Concert’s value shaved after early alopecia win

Article image
Vantage logo
September 21, 2018

Upcoming events – Phase II readouts loom for Concert and Reata

Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.

Vantage logo
October 25, 2017

Abbvie’s Jak flashes a warning for the whole class

Vantage logo
March 29, 2017

Vertex investors toast birth of the son of Orkambi

Vantage logo
March 06, 2017

Vertex’s cystic fibrosis strategy in tune with Concert buy

Vantage logo
December 15, 2016

Eucrisa thumbs up validates Pfizer’s takeover strategy – partly

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2020 Evaluate Ltd.